The mounting complexity of new modalities
in the biopharmaceutical
industry entails a commensurate level of analytical innovations to
enable the rapid discovery and development of novel therapeutics and
vaccines. Hydrophobic interaction chromatography (HIC) has become
one of the widely preferred separation techniques for the analysis
and purification of biopharmaceuticals under nondenaturing conditions.
Inarguably, HIC method development remains very challenging and labor-intensive
owing to the numerous factors that are typically optimized by a “hit-or-miss”
strategy (e.g., the nature of the salt, stationary phase chemistry,
temperature, mobile phase additive, and ionic strength). Herein, we
introduce a new HIC method development framework composed of a fully
automated multicolumn and multieluent platform coupled with in silico multifactorial simulation and integrated fraction
collection for streamlined method screening, optimization, and analytical-scale
purification of biopharmaceutical targets. The power and versatility
of this workflow are showcased by a wide range of applications including
trivial proteins, monoclonal antibodies (mAbs), antibody–drug
conjugates (ADCs), oxidation variants, and denatured proteins. We
also illustrate convenient and rapid HIC method development outcomes
from the effective combination of this screening setup with computer-assisted
simulations. HIC retention models were built using readily available
LC simulator software outlining less than a 5% difference between
experimental and simulated retention times with a correlation coefficient
of >0.99 for pharmaceutically relevant multicomponent mixtures.
In
addition, we demonstrate how this approach paves the path for a straightforward
identification of first-dimension HIC conditions that are combined
with mass spectrometry (MS)-friendly reversed-phase liquid chromatography
(RPLC) detection in the second dimension (heart-cutting two-dimensional
(2D)-HIC-RPLC-diode array detector (DAD)-MS), enabling the analysis
and purification of biopharmaceutical targets.